Skip to content
value.today
Vaccinogen Inc. logo

Vaccinogen Inc.

Total raised
$18 M
3 rounds on record
Latest round
$7 M
Oct 2012
First round on record
Dec 2008
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vaccinogen Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2012$7 MNo. 3$2 to $10 million

Vaccinogen Inc.: Raise no. 3, Oct 2012

Investors in this round

68 investors had bought by the notice of Jan 24, 2014: 68 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $13 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$14,542
Finders' fees
none
Paid to its own people
$339,800 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Maryland

People named in the notice

  • Andrew L. Tussing · Executive Officer
  • Michael G. Hanna, Jr. · Executive Officer, Director
  • Alan L. Cohen · Director
  • Daniel L. Fitzgerald · Director
  • Daniel L. Kane · Director
  • John L. Nicolis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Juli Youngblood (CRD 1943480) · broker-dealer VANGUARD CAPITAL (CRD 22081) · San Diego, CaliforniaSold in AZ, CA, CT, DC, NV, NY, UT, VA
  • John Blake (CRD 1014886) · broker-dealer VANGUARD CAPITAL (CRD 22081) · San Diego, CaliforniaSold in AZ, CA, CT, DC, NV, NY, UT, VA

Signed by Andrew L. Tussing, President. Source: SEC Form D and 1 amendment, newest notice filed Jan 24, 2014. Read the notice at the SEC.

equitySEC
Feb 2010$8 MNo. 2$2 to $10 million

Vaccinogen Inc.: Raise no. 2, Feb 2010

Investors in this round

25 investors had bought by the notice of Jun 3, 2011: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $35 M offered; $27 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,295,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew L. Tussing · Executive Officer
  • Michael G. Hanna, Jr. · Executive Officer, Director
  • Michael L. Kranda · Executive Officer, Director
  • Alan L. Cohen · Director
  • Daniel L. Fitzgerald · Director
  • Daniel L. Kane · Director
  • John L. Nicolis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew L. Tussing, Chief Operating Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 3, 2011. Read the notice at the SEC.

equitySEC
Dec 2008$4 MNo. 1$2 to $10 million

Vaccinogen Inc.: Raise no. 1, Dec 2008

Investors in this round

66 investors had bought by the notice of Feb 19, 2010: 66 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$5,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$356,250 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew L. Tussing · Executive Officer · Chief Operating Officer
  • Michael G. Hanna, Jr. · Executive Officer, Director · CEO and Chairman
  • David L. Hatt · Director · Board of Directors Member
  • Gregory H. Barnhill · Director · Board of Directors Member
  • John L. Nicolis · Director · Board of Directors Member
  • Tony L. Caplin · Director · Board of Directors Member

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew L. Tussing, Chief Operating Officer. Source: SEC Form D, newest notice filed Feb 19, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vaccinogen Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2014).

    SEC Form D · Jan 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2014

That is all the official record says: Vaccinogen Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

In its own words

How the company describes itself to search engines on its website, word for word.

“Welcome to Vaccinogen Inc, your personal guide to the top game developers and software providers, history facts, and today's connection with online casinos.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of Vaccinogen Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 68 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vaccinogen Inc.
NameRoleNamed in
Andrew L. TussingExecutive officerJan 2014
Michael G. Hanna, Jr.Executive officerJan 2014
Michael L. KrandaExecutive officerJun 2011
Alan L. CohenDirectorJan 2014
Daniel L. FitzgeraldDirectorJan 2014
Daniel L. KaneDirectorJan 2014
John L. NicolisDirectorJan 2014
Michael G. Hanna, Jr.DirectorJan 2014
Michael L. KrandaDirectorJun 2011
David L. HattBoard of Directors MemberMar 2010
Gregory H. BarnhillBoard of Directors MemberMar 2010
Tony L. CaplinBoard of Directors MemberMar 2010

About

American biotechnology company.